

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 8-K/A**  
**(Amendment No. 1)**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 9,**  
**2020**

---

**Aspira Women's Health Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34810**  
(Commission  
File Number)

**33-0595156**  
(IRS Employer  
Identification No.)

**12117 Bee Caves Road, Building Three,**  
**Suite 100, Austin, Texas**  
(Address of principal executive offices)

**78738**  
(Zip Code)

**Registrant's telephone number, including area code: (512) 519-**  
**0400**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.001 per share	AWH	The Nasdaq Stock Exchange

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

### **Explanatory Note**

This Amendment No. 1 on Form 8-K/A ("this Amendment") is an amendment to the Current Report on Form 8-K originally filed by Aspira Women's Health Inc. (the "Company") with the Securities and Exchange Commission on November 12, 2020 (the "Original 8-K"), which reported, among other things, the appointment of Sandra Brooks, M.D. as a director of the Company, effective November 9, 2020. At the time of the Original 8-K, the board of directors of the Company (the "Board") had not made a determination regarding any committee appointments for Dr. Brooks. This Amendment is being filed solely to supplement Item 5.02 of the Original 8-K to include additional disclosure regarding Dr. Brooks' committee appointment. This Amendment does not otherwise amend, update or change any other disclosures contained in the Original 8-K.

#### **Item 5.02           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 10, 2020, the Board appointed Dr. Brooks to serve on the Compensation Committee of the Board, effective December 10, 2020.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2020

By:

Aspira Women's Health Inc.

/s/ Robert Beechey

Robert Beechey  
Chief Financial Officer

---